推荐产品
质量水平
方案
≥98% (TLC)
表单
powder
旋光性
[α]25/D -5.4°, c = 4.9 in 1 M HCl(lit.)
颜色
white to off-white
mp
202-203 °C (lit.)
溶解性
H2O: soluble
ethanol: soluble
ε (消光系数)
8,700 at 294 nm at 1 M
创始人
Merck & Co., Inc., Kenilworth, NJ, U.S.
SMILES字符串
[H]\C(=C(/[H])C(O)=O)C(O)=O.CC(C)(C)NC[C@H](O)COc1nsnc1N2CCOCC2
InChI
1S/C13H24N4O3S.C4H4O4/c1-13(2,3)14-8-10(18)9-20-12-11(15-21-16-12)17-4-6-19-7-5-17;5-3(6)1-2-4(7)8/h10,14,18H,4-9H2,1-3H3;1-2H,(H,5,6)(H,7,8)/b;2-1-/t10-;/m0./s1
InChI key
WLRMANUAADYWEA-NWASOUNVSA-N
基因信息
human ... ADRB1(153) , ADRB2(154) , ADRB3(155)
正在寻找类似产品? 访问 产品对比指南
应用
Timolol maleate has been used as an adrenergic β-blocker for evaluating cardiovascular functions in mice5. It has also been used for evaluating the uptake of 86Rb+ in rat cardiomyocytes6.
生化/生理作用
Timolol maleate is a class II anti-arrhythmic agent that functions as a non-selective β-adrenoceptor antagonist, a vasodilator and an anti-glaucoma agent. Studies have reported that timolol maleate can be used for the treatment of infantile hemangioma (IH)7.
特点和优势
This compound was developed by Merck & Co., Inc., Kenilworth, NJ, U.S.. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
制备说明
Timolol maleate is soluble in ethanol and water.
警示用语:
Warning
危险声明
危险分类
Acute Tox. 4 Oral - Repr. 2
储存分类代码
11 - Combustible Solids
WGK
WGK 3
个人防护装备
Eyeshields, Gloves, type P3 (EN 143) respirator cartridges
法规信息
监管及禁止进口产品
Journal of ocular pharmacology, 8(3), 183-190 (1992-01-01)
An ocular hypertensive rabbit eye model was used to study the effect of L- and D-timolol on retinal and choroidal blood flow. Ocular hypertension was induced artificially by raising the intraocular pressure to 40 mmHg which reduced the ocular blood
Pediatric dermatology, 29(1), 28-31 (2011-12-14)
Therapeutic options for superficial infantile hemangiomas (IH) are limited. Recently, timolol maleate gel, a topical nonselective beta-blocker, has been reported as a potentially effective treatment for superficial IH. This study is an extension of a previously published pilot study designed
PloS one, 8(2), e49730-e49730 (2013-03-08)
Optic nerve atrophy caused by abnormal intraocular pressure (IOP) remains the most common cause of irreversible loss of vision worldwide. The aim of this study was to determine whether topically applied IOP-lowering eye drugs affect retinal ganglion cells (RGCs) and
Current eye research, 18(5), 381-390 (1999-06-18)
To evaluate the effects of topical carteolol or timolol on tissue circulation in the iris and posterior choroid. After a topical instillation of 20 microl of 2% carteolol, 0.5% timolol, or physiological saline (for control) into one eye, and physiological
PloS one, 7(9), e45079-e45079 (2012-10-03)
The first goal of medical therapy in glaucoma is to reduce intraocular pressure (IOP), and the fixed-combination medications are needed to achieve sufficiently low target IOP. The aim of this systematic review and meta-analysis is to evaluate IOP-lowering effect of
我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门